We are live on ! Find out more
ALXN

Alexion Pharmaceuticals
ALXN

Delisted

ALXN was delisted on the 20th of July, 2021.

561 hedge funds and large institutions have $26B invested in Alexion Pharmaceuticals in 2017 Q1 according to their latest regulatory filings, with 84 funds opening new positions, 220 increasing their positions, 204 reducing their positions, and 61 closing their positions.

New
Increased
Maintained
Reduced
Closed

38% more first-time investments, than exits

New positions opened: 84 | Existing positions closed: 61

2% more funds holding

Funds holding: 548561 (+13)

8% more repeat investments, than reductions

Existing positions increased: 220 | Existing positions reduced: 204

2% more call options, than puts

Call options by funds: $261M | Put options by funds: $257M

3% less capital invested

Capital invested by funds: $26.9B → $26B (-$932M)

29% less funds holding in top 10

Funds holding in top 10: 2417 (-7)

Holders
561
Holders Change
+13
Holders Change %
+2.37%
% of All Funds
13.97%
Holding in Top 10
17
Holding in Top 10 Change
-7
Holding in Top 10 Change %
-29.17%
% of All Funds
0.42%
New
84
Increased
220
Reduced
204
Closed
61
Calls
$261M
Puts
$257M
Net Calls
+$4.33M
Net Calls Change
+$22.1M
Name Holding Trade Value Shares
Change
Change in
Stake
PP
276
Paloma Partners
Connecticut
$2.21M +$2.35M +18,264 New
Nomura Holdings
277
Nomura Holdings
Japan
$2.21M -$1.82M -14,106 -44%
Simplex Trading
278
Simplex Trading
Illinois
$2.17M +$1.24M +9,629 +116%
CAM
279
Covenant Asset Management
New Jersey
$2.16M +$94.6K +734 +4%
Creative Planning
280
Creative Planning
Kansas
$2.1M +$19K +147 +0.9%
PG
281
PEAK6 Group
Illinois
$2.07M +$2.2M +17,071 New
SSA
282
Schonfeld Strategic Advisors
New York
$2.06M -$2.46M -19,119 -53%
SIM
283
Sentry Investment Management
Wisconsin
$2.06M -$101K -783 -4%
SCM
284
Shelton Capital Management
Colorado
$2.04M +$190K +1,475 +10%
EU
285
Emory University
Georgia
$2.03M -$117K -904 -5%
COPPSERS
286
Commonwealth of Pennsylvania Public School Employees Retirement System
Pennsylvania
$2.02M +$491K +3,807 +30%
AB
287
Amalgamated Bank
New York
$2.01M -$913K -7,080 -30%
DILIC
288
Dai-ichi Life Insurance Company
Japan
$1.97M -$2.19M -16,965 -51%
Squarepoint
289
Squarepoint
New York
$1.96M +$2.08M +16,132 New
HighTower Advisors
290
HighTower Advisors
Illinois
$1.93M -$43.6K -338 -2%
SIM
291
Spark Investment Management
New York
$1.93M +$2.05M +15,900 New
SF
292
Synovus Financial
Georgia
$1.91M +$90.4K +701 +5%
PCM
293
Proxima Capital Management
New York
$1.82M
AC
294
Allstate Corporation
Illinois
$1.81M -$3.38M -26,213 -64%
Baird Financial Group
295
Baird Financial Group
Wisconsin
$1.77M +$1.29M +10,028 +219%
NB
296
Norinchukin Bank
Japan
$1.77M +$128K +992 +7%
KRS
297
Kentucky Retirement Systems
Kentucky
$1.75M -$241K -1,872 -12%
ID
298
Integral Derivatives
New York
$1.68M +$1.78M +13,844 New
LSERS
299
Louisiana State Employees Retirement System
Louisiana
$1.67M -$38.7K -300 -2%
Envestnet Asset Management
300
Envestnet Asset Management
Illinois
$1.66M -$85.3K -662 -5%

ALXN Hedge Fund Activity: Q1 2017 in Review

561 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Alexion Pharmaceuticals (ALXN) for Q1 2017, worth a combined $26B — down 3.5% from $26.9B a quarter earlier.

Buyers outnumbered sellers: 84 funds opened new ALXN positions and 61 closed out — a net gain of 23 holders — while 220 added to existing stakes and 204 trimmed.

The largest buyer was BlackRock, adding an estimated $2.32B. The largest seller was Capital Research Global Investors, cutting an estimated $922M.

  • 561 institutional investors held Alexion Pharmaceuticals (ALXN) as of Q1 2017, up from 548 in Q4 2016.
  • Funds reported $26B of Alexion Pharmaceuticals stock for Q1 2017, down 3.5% quarter-over-quarter.
  • 84 funds opened new Alexion Pharmaceuticals positions in Q1 2017 and 61 closed out, a net change of +23 holders.
  • The largest Alexion Pharmaceuticals buyer in Q1 2017 was BlackRock, an estimated $2.32B added.
  • The largest Alexion Pharmaceuticals seller in Q1 2017 was Capital Research Global Investors, an estimated $922M sold.

Based on aggregated 13F filings for Q1 2017.